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Abstract
Background: Squamous cell carcinoma of the head and neck (SCCHN) remains a prevalent and devastating disease.
Recently, there has been an increase in SCCHN cases that are associated with high-risk human papillomavirus (HPV)
infection. The clinical characteristics of HPV-positive and HPV-negative SCCHN are known to be different but their
molecular features are only recently beginning to emerge. MicroRNAs (miRNAs, miRs) are small, non-coding RNAs that are
likely to play significant roles in cancer initiation and progression where they may act as oncogenes or tumor suppressors.
Previous studies in our laboratory showed that miR-363 is overexpressed in HPV-positive compared to HPV-negative
SCCHN cell lines, and the HPV type 16-E6 oncoprotein upregulates miR-363 in SCCHN cell lines. However, the functional
role of miR-363 in SCCHN in the context of HPV infection remains to be elucidated.
Methods: We analyzed miR-363 levels in SCCHN tumors with known HPV-status from The Cancer Genome Atlas (TCGA)
and an independent cohort from our institution. Cell migration studies were conducted following the overexpression of
miR-363 in HPV-negative cell lines. Bioinformatic tools and a luciferase reporter assay were utilized to confirm that
miR-363 targets the 3’-UTR of myosin 1B (MYO1B). MYO1B mRNA and protein expression levels were evaluated following
miR-363 overexpression in HPV-negative SCCHN cell lines. Small interfering RNA (siRNA) knockdown of MYO1B was
performed to assess the phenotypic implication of reduced MYO1B expression in SCCHN cell lines.
Results: MiR-363 was found to be overexpressed in HPV-16-positive compared to the HPV-negative SCCHN tumors.
Luciferase reporter assays performed in HPV-negative JHU028 cells confirmed that miR-363 targets one of its two
potential binding sites in the 3’UTR of MYO1B. MYO1B mRNA and protein levels were reduced upon miR-363
overexpression in four HPV-negative SCCHN cell lines. Increased miR-363 expression or siRNA knockdown of MYO1B
expression reduced Transwell migration of SCCHN cell lines, indicating that the miR-363-induced migration attenuation
of SCCHN cells may act through MYO1B downregulation.
Conclusions: These findings demonstrate that the overexpression of miR-363 reduces cellular migration in head and
neck cancer and reveal the biological relationship between miR-363, myosin 1b, and HPV-positive SCCHN.
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Background
Head and neck cancer ranks sixth amongst cancers
worldwide and represents a heterogeneous collection of
neoplasms, derived from the upper aerodigestive tract
[1, 2]. The most common type, squamous cell carcinoma
of the head and neck (SCCHN), occurs in the oral cavity,
pharynx, and larynx. Tobacco use and alcohol
consumption are the predominant risk factors for
SCCHN. Recently, human papillomavirus (HPV) infec-
tion has been noted as an etiologic agent for a subset of
SCCHN, specifically oropharyngeal malignancies, includ-
ing tumors of the base of tongue and tonsil [3]. Despite
advances in diagnosis and treatment, the five-year sur-
vival rate of 40–50 % has only incrementally improved
in the last 20 years [4]. Prophylactic vaccination against
high-risk HPV types may prevent a substantial number
of oropharyngeal carcinomas in the future. However, the
prolonged course of HPV carcinogenesis and the current
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prevalence of HPV-positive SCCHN warrant further in-
vestigation of its pathogenesis.
HPVs are small, circular, double-stranded, non-
enveloped DNA viruses that infect the basal layer of
squamous epithelial cells through abrasions or lesions in
skin or mucosa. The relationship between high-risk HPV
types (for example, HPV-16 and HPV-18) and cervical,
anogenital, and oral cancers is well-established [5]. E6
and E7 oncoproteins from high-risk HPV types are es-
sential for cellular transformation and functional inacti-
vation of the tumor suppressor proteins p53 and
retinoblastoma, respectively [1].
While the overall incidence of SCCHN has steadily de-
clined, the prevalence of HPV-positive SCCHN cancers,
specifically in developed nations, has markedly increased
in the past decade due to a shift in sexual practices.
SCCHN patient tumors from the United States demon-
strate a 30 % HPV positivity rate [5], with more than
90 % of HPV-associated SCCHN due to HPV-16 [5].
HPV-positive and HPV-negative SCCHN demonstrate
different clinical and demographic characteristics, lead-
ing some to classify them as distinct cancers [6]. HPV-
positive SCCHN patients are generally younger men
(40–55 years) from a higher socioeconomic status with
minimal tobacco and alcohol exposure [5]. Tumors with
a high viral load generally have a better prognosis com-
pared to HPV-negative or low viral load tumors [7]. Des-
pite late stage presentations due to early metastasis to
secondary lymphoid tissues [8], HPV-positive tumors
have a greater response to chemotherapy, radiation, and
surgery [8]. HPV-positive tumors demonstrate improved
immune system activation to viral antigens [9], lower re-
currence rates [10], and more favorable disease out-
comes [1] compared to HPV-negative head and neck
tumors. While p53 contains inactivating mutations in
more than half of HPV-negative oral cancers, it is rarely
mutated in HPV-positive SCCHN [8]. The complex mo-
lecular mechanisms underlying the divergence in out-
come depending on HPV-status is not well-understood.
Elucidating the role of microRNAs (miRNAs, miRs) is
one approach to evaluating the molecular differences be-
tween HPV-positive versus HPV-negative SCCHN.
MiRNAs are ~22 nucleotide-long, endogenously
encoded, single-stranded RNAs that modulate the ex-
pression of over 50 % of human genes at the post-
transcriptional level [11, 12]. MiRNAs are transcribed ei-
ther from their own promoters or are processed from
introns of protein-coding genes [13]. Precursor miRNAs
(~70 nucleotides long) are exported into the cytoplasm
where they are further processed into mature miRNAs
and incorporated into the RNA-induced silencing com-
plex (RISC) as a single strand [14]. RISC-associated miR-
NAs then pair with complementary sequences in the
3’-untranslated regions (UTRs) of one or more target
mRNAs [14]. MiRNAs function as negative post-
transcriptional regulators of gene expression by several
mechanisms, including (1) site-specific cleavage of
mRNAs; (2) enhanced mRNA degradation; and (3) in-
hibition of mRNA translation [14]. An mRNA may be
targeted by several miRNAs while a single miRNA may
target multiple mRNAs, thereby regulating dozens of
genes.
MiRNAs regulate several cellular processes such as
proliferation, differentiation, and apoptosis. Studies in
chronic lymphocytic leukemia were the first to reveal
the relationship between miRNAs and cancer pathogen-
esis in 2002 [15]. Since then, aberrant miRNA expres-
sion has been implicated in the initiation and
progression of numerous hematological cancers and
solid tumors, including SCCHN [16–18]. Notably, differ-
ential miRNAs expression profiles have been described
in noncancerous versus tumor tissues [16, 19, 20]. MiR-
NAs may function as tumor suppressors or oncogenes
depending on whether they target the mRNA of onco-
genes or tumor suppressors, respectively. Consequently,
confirming protein targets of a miRNA is critical in de-
lineating their role in cancer. However, while several
SCCHN miRNA profiling studies have been recently
performed, the functional significance of dysregulated
miRNAs in SCCHN is still poorly understood, especially
in the context of HPV infection [20–31].
Although miR-363 is a member of the oncogenic miR-
17 ~ 92 family of clusters [32], recent studies indicate
that it may also possess tumor suppressor functions
[33–36]. Thus, its role in oncogenesis is rather contro-
versial at the present time. We previously reported miR-
363 overexpression in HPV-positive SCCHN cell lines
and showed that the HPV-16 E6 oncogene directly upre-
gulates miR-363 [30]. In the current study, we have in-
terrogated miR-363 expression in human SCCHN
tumors and the phenotypic significance of miR-363 over-
expression in SCCHN cell lines. MiRNA target predic-
tion analysis suggested that miR-363 may target the
3’UTR of myosin 1B (MYO1B), a motor protein involved
in cellular motility [37, 38]. Using luciferase reporter as-
says, we confirmed that miR-363 downregulates MYO1B
expression in SCCHN cells by directly targeting the
3’UTR of MYO1B mRNA. By investigating the conse-
quences of HPV-16 E6-mediated miR-363 expression in
vitro, we aim to better resolve the clinicopathological
features of HPV-positive SCCHN and identify prognostic
markers of disease outcome, as well as new targets and
therapeutic agents.
Methods
Patients
This study was approved by the Institutional Review
Board of the University of Pittsburgh (protocol #99-069).
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Written informed consent was obtained from all pa-
tients. No children were enrolled in this study.
Bioinformatics
MicroRNA data were extracted from The Cancer Gen-
ome Atlas (TCGA) Research Network (http://cancergen-
ome.nih.gov/) portal isoform files for SCCHN tumors
(accessed May 15, 2013). The reads per million miRNAs
mapped data unit was evaluated, which represents each
miRNA read count as a fraction of the total miRNA
population for a particular tumor. Multiple reads from
individual isoforms were combined into a single read
count. The HPV-status of TCGA SCCHN tumors was
noted according to the cBio Cancer Genomics Platform
SCCHN database [39].
SCCHN tumors
Forty-one SCCHN tissues were obtained from patients
according to Institutional Review Board protocol #99–
069. Upon surgical removal, a portion of all tissues was
sent to pathology for tumor staging and the remainder
was flash frozen until further processing.
Cell lines and maintenance
The HPV-negative human SCCHN cell lines PCI13 and
PCI30 were kindly provided by Dr. Theresa Whiteside
(University of Pittsburgh Cancer Institute, Pittsburgh,
PA) while the JHU028 and JHU029 cell lines were ob-
tained from Dr. Joseph A. Califano (Johns Hopkins Uni-
versity School of Medicine, Baltimore, MD). PCI13 and
PCI30 were cultured in Dulbecco's Modified Eagle's
Medium (Lonza, Walkersville, MD) while JHU028 and
JHU029 were cultured in RPMI-1640 (Lonza). All cells
were supplemented with 10 % heat-inactivated FBS, 1 X
penicillin/streptomycin solution (Lonza), and 2 mM L-
glutamine (Gibco). Cell lines were maintained in a hu-
midified cell incubator at 37 °C, 5 % CO2 atmosphere.
Transfections
Cells were seeded to 50 % confluency in 6-well plates in
antibiotic-free media 24 h prior to transfection. Cells
were transfected with 50 nM premiR-363, negative pre-
miR control (Applied Biosystems, Foster City, CA), or
50 nM small interfering RNA (siRNA) against MYO1B
(ThermoFisher Scientific, San Jose, CA) using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) and Opti-MEM®
(Gibco, Grand Island, NY). A FAM-labeled control pre-
miR (Applied Biosystems) or a Block-it fluorescent
oligonucleotide with no human homologous sequences
(Invitrogen) was used as a control and to measure trans-
fection efficiency in premiR and siRNA experiments, re-
spectively. Cells were harvested 48 h after transfection
and RNA and proteins were isolated for various assays
as described below.
DNA and RNA isolation
The Dneasy Blood & Tissue kit (Qiagen, Valencia, CA) was
used to isolate DNA from SCCHN tissues according to the
manufacturer’s protocol. Total RNA was isolated from
SCCHN tissues and cell lines grown to 80-90 % confluency
using the UltraspecTM RNA Isolation System (Biotecx,
Houston, TX) according to the manufacturer’s protocol.
HPV genotyping and quantitative real time RT-PCR
HPV status of the tumor tissues was assessed using the
MY09/MY11 primer set, which amplifies a conserved re-
gion of the HPV L1 gene [40]. The glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene was used as a
loading control using 5′-CGACCACTTTGTCAAGCTCA-
3′ as the forward primer and 5′-AGGGGTCTACATG
GCAACTG-3′ as the reverse primer. All PCR reactions
were performed using 20 ng template DNA, 200 μM of
each deoxynucleoside triphosphate (dNTP), 0.5 μM of each
primer, and 0.5 units of Taq polymerase and the associated
buffer (Promega, Madison, WI). Thermocycler conditions
for all PCR reactions were 94 °C for 5 min; 35 cycles of 94 °
C for 30 s, 57 °C for 30 s, and 72 °C for 30 s; and 72 °C for
10 min. The PCR-amplified DNA was visualized by agarose
gel electrophoresis.
HPV-16 E6, HPV-16 E7, and MYO1B expression levels
were measured by quantitative real-time RT-PCR (qRT-
PCR) using the iTaqTM Universal SYBR® Green One-Step
Kit (Bio-Rad) and the Real-Time thermocycler iQ5
(Bio-Rad, Hercules, CA, USA). The E6 forward primer
5′-AATGTTTCAGGACCCACAGG-3′, E6 reverse pri-
mer 5′-CAGCTGGGTTTCTCTACGTG-3′, E7 forward
primer 5′-CATGGAGATACACCTACATTGCAT-3′,
and E7 reverse primer 5′-GAACAGATGGGGCAC
ACAAT-3′ were used to genotype HPV-positive SCCHN
tissue samples. A 127 bp region of the MYO1B gene was
amplified using the forward primer 5′-GGTCTGGT
GTGGAGGTCCTA-3′ and the reverse primer 5′-
CGTTGCTTCCTCAGGTCTTC-3′. HPV-16 E6, HPV-
16 E7, and MYO1B mRNA levels were normalized to
the GAPDH mRNA levels, using the forward primer 5′-
CAGCCTCAAGATCATCAGCA-3′ and the reverse pri-
mer 5′-TGTGGTCATGAGTCCTTCCA-3′, amplifying
a 106 bp region. DNase I-treated total RNA (60 ng) was
used for each reaction, and all the reactions were per-
formed in triplicate. Relative mRNA expression levels
were calculated using the 2-ΔΔCT values [41].
Mature miR-363 expression was confirmed by qRT-
PCR using the TaqMan® MicroRNA Reverse Transcrip-
tion Kit and the TaqMan® MicroRNA Assays (Applied
Biosystems, Foster City, CA, USA) and the Real-Time
thermocycler iQ5 (Bio-Rad, Hercules, CA, USA). The
qRT-PCR experiments utilized stem-loop primers de-
signed to amplify processed, mature miRNA. Total RNA
(50 ng) was used for each reaction. All reactions were
Chapman et al. BMC Cancer  (2015) 15:861 Page 3 of 10
performed in triplicate according to the manufacturer’s
instructions. MiRNA levels for each sample were nor-
malized to small nucleolar (sno) RNU43 levels. Relative
miRNA expression levels were calculated using the 2-
ΔΔCT values [41].
Transwell migration assay
The HPV-negative SCCHN cell line, JHU028, was trans-
fected with premiR-363 or an siRNA against MYO1B
along with appropriate controls as described earlier.
Forty-eight hours after transfection, cells were harvested
and reseeded into 24-well 8 μM pore Transwell inserts
(Corning) in serum-free media. The lower chambers of
the Transwell plate were filled with 20 % FBS/RPMI
media to serve as a chemoattractant. Transwells were
stained with 0.1 % crystal violet at 1, 3, and 5 h following
reseeding. Cells were photographed under the micro-
scope and counted. The mean of eight fields from four
separate trials was used to calculate the average number
of migratory cells.
Mutagenesis of the miR-363 binding sites in the MYO1B
3’ UTR
The MYO1B 3’UTR (1.4 kb; chr2:192,288,687-
192,290,115) was PCR amplified using the forward pri-
mer 5’-GGACTAGTAACCGTCTCCTTGAAGTTGC-3’
and the reverse primer 5′-GGAAGCTTGGCACAAG
GCAAGAAGAATC-3′. The primers were designed with
a SpeI restriction site on the forward primer and a Hin-
dIII site on the reverse primer to aid in directional clon-
ing of the amplified DNA into the pMIR-REPORTTM
vector (Applied Biosystems). The orientation of the
inserted fragment was confirmed by restriction enzyme
digestion and sequencing.
Deletion primers and the QuikChange XL Site-Directed
Mutagenesis Kit (Agilent Technologies; Santa Clara, CA)
was used to delete miR-363 binding site 1 (BS1)
(chr2:192,288,731-192,288,738) or binding site 2 (BS2)
(chr2: 192,289,618-192,289,625) from the 3’UTR of the
MYO1B gene cloned into the pMIR-REPORTTM vector
(Applied Biosystems). BS1 was deleted using the forward
primer 5’-CTACTTTCATGGACTTGTTCCTTTGTAAT
A-TGGTTTTGTTTTATTTGGGGTTCATTGTATG-3’
and the reverse primer 5’-CATACAATGAACCCCAAA
TAAAACAAAACCA-TATTACAAAGGAACAAGTCCA
TGAAAGTAG-3’. BS2 was deleted using the forward
primer 5’-CCATTCAGATAGCAGTAAAACATTCTG
TATGAT-AAACATCCAAGATCTTTTTTGAAAG-3’ and
the reverse primer 5’-CTTTCAAAAAAGATCTTGGAT
GTTT-ATCATACAGAATGTTTTACTGCTATCTGAA
TGG-3’. Deletion mutants were confirmed by restriction
enzyme digestion and DNA sequencing.
Luciferase reporter assay
HPV-negative JHU028 cells were plated at 30,000 cells
per well in 24-well plates (Corning). After 24 h, cells
were transfected using Lipofectamine 2000 (Invitrogen)
and Opti-MEM® (Life Technologies). The pMIR-
REPORTTM MYO1B wild-type, 3’UTR BS1 or BS2 dele-
tion constructs (500 ng) were co-transfected with 20 ng
phRL-TK and 50 nM pre-miRs. All transfection experi-
ments were repeated at least four times. Luciferase activ-
ity was measured 48 h post-transfection using the Dual
Luciferase Reporter Assay System (Promega) according
to manufacturer’s instructions and the Synergy 2 Lumin-
ometer (Biotek). RLU (Firefly/Renilla) activity was nor-
malized to the MYO1B wild-type 3’ UTR co-transfected
with phRL-TK only.
Western blotting
Cells were lysed with radioimmunoprecipitation assay
(RIPA) buffer at 4 °C directly on the 6 well-plate 48 h
post-transfection with premiR-363 and the premiR nega-
tive control. Proteins (50 μg) from total cell lysates were
separated on a 4-15 % SDS-polyacrylamide gradient gel
(Bio-Rad) and transferred to Immobilon-P PVDF mem-
brane (Millipore, Billerica, MA). After blocking, blots
were incubated with a primary rabbit polyclonal anti-
body against MYO1B and a secondary anti-rabbit horse-
radish peroxidase antibody (both Santa Cruz
Biotechnology, Santa Cruz, CA). A mouse monoclonal
antibody against GAPDH (Chemicon, Billerica, MA) was
used to normalize protein loading. Blots were visualized
using the Western Lightning Plus ECL Substrate (Perkin
Elmer; Waltham, MA), developed, and quantified by
densitometry using AlphaView software by ProteinSim-
ple (Santa Clara, CA).
Statistical analysis
Statistical analysis was carried out using two-tailed t-tests.
Data was considered significant at a value of p < 0.05.
Results
MiR-363 expression is significantly upregulated in head
and neck tumors
Our analysis of 280 TCGA SCCHN tumors (245 HPV-
negative and 35 HPV-positive) revealed that miR-363 ex-
pression is significantly increased (p < 0.001) in HPV-
positive tumors compared to HPV-negative tumors
(Figure 1a) [42]. We also examined an additional cohort
of 41 SCCHN patients (24 HPV-positive and 17 HPV-
negative tumors) treated at the University of Pittsburgh
Cancer Institute (UPCI) between 2006 and 2009 (Fig. 1b,
Table 1). Patient characteristics are further described in
detail in Additional file 1. DNA PCR was performed to
confirm the HPV status of tumor tissues (data not
shown). HPV-positive SCCHN tissues expressed higher
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miR-363 levels compared to HPV-negative SCCHN sam-
ples as determined by qRT-PCR analysis (two-tailed t-
test, p < 0.01; Fig. 1b). These data are consistent with our
previous in vitro studies where HPV-positive SCCHN
cell lines were found to have higher levels of miR-363
expression than the HPV-negative cell lines[30].
Exogenous miR-363 suppresses the migratory ability of
HPV-negative SCCHN cells
To determine the possible biological functions of
miR-363, we transiently transfected HPV-negative
SCCHN cell lines with premiR-363 or a negative
premiR control and examined the effects on cell mi-
gration, proliferation, cell cycle and colony forma-
tion. Transwell migration assays showed a significant
decrease in the number of migratory JHU028 cells
overexpressing miR-363 compared to control cells at
1, 3, and 5 h (Fig. 2). Overexpression of miR-363 in
HPV-negative SCCHN cell lines did not significantly
affect cellular proliferation as examined by cell
counting (Additional file 2), propidium iodide cell
cycle (Additional file 3), and bromodeoxyuridine
(BrdU; Additional file 4) cell cycle assays. Further,
soft agar colony formation assays showed no differ-
ence in anchorage-independent growth between
JHU028 cells overexpressing miR-363 and negative
control cells (data not shown). Collectively, these re-
sults indicate that elevated miR-363 expression pri-
marily reduces migration of SCCHN cell lines.
MiR-363 targets the MYO1B 3’ UTR and reduces MYO1B
expression
We have previously shown that 150 genes are downreg-
ulated in HPV-positive SCCHN tissues compared to
HPV-negative SCCHN[43]. Since miRNAs negatively
regulate their target genes, we identified potential miR-
363 target genes using bioinformatic prediction tools
(TargetScan, miRanda, Diana) [44–46]. A comparison of
the putative target genes predicted by all three databases
and the genes downregulated in HPV-positive cell lines
identified 10 potential miR-363 target genes [43]. Of
these, MYO1B was tested in our studies since its 3’ UTR
contains two potential miR-363 binding sites (see Fig. 4a).
Fig. 1 MiR-363 expression in SCCHN tissues a MiR-363 expression in The Cancer Genome Atlas SCCHN tumors. HPV-negative tumors possessed
an average miR-363 reads per million miRNA mapped of 11.17 while HPV-positive tumors averaged a value of 37.58, indicating a 3.36-fold increase
in miR-363 expression in HPV-positive tissues; *p < 0.001. b QRT-PCR analysis of miR-363 in HPV-positive and HPV-negative SCCHN tissues. Black
bars, HPV-16-positive SCCHN samples; gray bars, HPV-negative SCCHN samples. Intensity values are relative to the HPV-negative SCCHN sample
with the lowest miR-363 expression, which was arbitrarily assigned a value of 1; *p < 0.01 for HPV-positive samples compared to the HPV-negative
samples; BOT, base of tongue; no RT, no reverse transcriptase added
Table 1 Detailed demographics of SCCHN tissues
HPV-16-positive HPV-negative
Age, mean (SD) 55.6 (7.1) 64.2 (11.2)
Gender, n (%)
Males 20 (83 %) 12 (71 %)
Females 4 (17 %) 5 (29 %)
Tumor location
Mouth* 1 3
Tongue 1 3
Vallecula 1 0
Base of tongue 8 4
Oropharynx 0 3
Tonsil 13 4
Tumor stage
T1NXMX 2 3
T2NXMX 21 5
T3NXMX 1 2
T4NXMX 0 6
Unknown 0 1
* Mouth samples include mouth, gum, and cheek
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Additionally, myosins are ubiquitous motor proteins in-
volved in cellular processes such as motility [47–49].
MYO1B expression at both the mRNA and protein
levels was reduced upon miR-363 overexpression in four
HPV-negative SCCHN cell lines (Fig. 3). A 68-73 % de-
crease in MYO1B mRNA expression was noted when
miR-363 was overexpressed in SCCHN cell lines. How-
ever, there was no significant difference in MYO1B pro-
tein expression between HPV-positive vs. HPV-negative
and primary vs. metastatic SCCHN tumors as detected
by immunohistochemistry using an oropharyngeal tissue
microarray (Additional file 5). To test whether MYO1B
was a direct target of miR-363, luciferase reporter assays
were performed in JHU028 cells with premiR-363 and
reporter plasmids (with wild-type MYO1B 3’ UTR or the
MYO1B 3’ UTR with BS1 or BS2 deletion, cloned down-
stream of the firefly luciferase gene in the pMiR-
REPORT™ vector). As shown in Fig. 4b, miR-363 mark-
edly reduced firefly luciferase activity of pMiR-REPORT™
plasmid containing the wild-type MYO1B 3’ UTR or a
plasmid lacking the BS2. Taken together, these studies
reveal that miR-363 binding site 1 (chr2:192,288,731-
192,288,738) plays a functionally significant role in the
regulation of MYO1B expression by this miRNA in head
and neck cancer cell lines.
siRNA knockdown of MYO1B reduces cell migration in
HPV-negative SCCHN cells
In order to verify whether miR-363-mediated reduction
in cellular migration is directly related to decreased
MYO1B expression, JHU028 cells were transfected with
an siRNA against MYO1B. As shown in Fig. 5a and b,
knockdown of MYO1B via siRNA in HPV-negative
SCCHN cells reduced Transwell migration compared to
cells expressing a negative control siRNA. These effects
were similar to those obtained with miR-363 overexpres-
sion, indicating that miR-363-induced migration attenu-
ation of SCCHN cells acts through MYO1B
downregulation.
Discussion
SCCHN is a common and severe malignancy of the
aerodigestive tract that is often diagnosed at late stages
(III or IV). While advancements in surgery, chemother-
apy, and radiation treatment have improved over time,
patients often succumb to chemoradiation resistance,
primary tumor invasion, metastasis, or recurrence. Not-
ably, a number of studies indicate that HPV status is the
strongest predictor of local recurrence, disease-specific
survival, and overall survival in patients with SCCHN
[50–52]. The heterogeneity of SCCHN malignancies
Fig. 2 MiR-363 reduces the migratory ability of HPV-negative SCCHN cells a JHU028 cells transfected with premiR-363 exhibited decreased Transwell
migration at 1, 3, and 5 h as compared to cells transfected with a negative premiR control. b Quantification of cell migration data from A. *p < 0.01
Fig. 3 MiR-363 overexpression decreases MYO1B mRNA and protein expression a qPCR analysis for relative MYO1B mRNA levels following pre-miR-363
transfection as determined by the 2-ΔΔCT method. Data were normalized to fold induction over negative control siRNA. b Western blot analysis of MYO1B
and GAPDH protein expression. c Relative MYO1B:GAPDH levels obtained from densitometry of the blot shown in B
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contributes to the difficulty in treating patients with gen-
eric cancer protocols; personalized treatments based on
tumor signatures may serve as an efficacious comple-
ment to current standards of care. Exploiting differences
in miRNA expression between HPV-positive and HPV-
negative SCCHN tissues and cell lines is one method of
dissecting the complexity of tumor biology.
MicroRNAs are a rapidly developing field within cancer
biology. MiRNA expression profiling studies have been re-
ported in numerous solid tumor and hematological cancers.
However, among noted deregulated miRNAs, few have
been functionally validated and a limited number of poten-
tial targets have been confirmed. This gap in knowledge
represents a significant roadblock in the development and
application of miRNA-based cancer therapeutics.
Few HPV-specific SCCHN miRNA profiling studies
have been performed to date. We previously reported 11
differentially expressed miRNAs between HPV-positive
and HPV-negative SCCHN cell lines [30]. Of these, three
(miR-363, −497, and −33) were up-regulated and eight
were down-regulated (miR-155, 181a, 181b, −29 s, −218,
−222, −221, and −142-5p) in HPV-positive cell lines.
Lajer et al. reported similar findings with miR-363 as the
most up-regulated miRNA in HPV-associated oropha-
ryngeal cancer in a Danish population; miR-127-3p was
the most down-regulated [27]. Comparisons between
HPV-positive cervical and SCCHN tumor miRNA profiles
reveal that the miR-15a/miR-16/miR195/miR-497 family,
miR-143/miR-145 and the miR-106-363 cluster appear to
be altered by HPV E6 and E7 oncoproteins [23].
MiR-363 is a member of the miR-17 ~ 92 family of
clusters, which is composed of three clusters of
0
0.2
0.4
0.6
0.8
1
1.2
1.4
R
el
at
iv
e 
L
u
ci
fe
ra
se
 E
xp
re
ss
io
n
A B
* *
Fig. 4 MiR-363 targets the 3’ UTR of MYO1B a Schematic representation of the 3’UTR of MYO1B with two complementary miR-363 target sites. Below,
mature miR-363 sequences aligned to target sites as predicted by TargetScan, miRanda, and Diana. b MiR-363 targets binding site 1 within the MYO1B
3’-UTR. Four constructs were created that contained the wild-type MYO1B 3’ UTR, 3’ UTR with BS1 or BS2 deletion, and 3’ UTR with both BS1 and BS2
deletions, cloned downstream of the firefly luciferase gene in the pMiR-REPORT™ vector. Each of the constructs were transfected separately into
JHU028 cells. MiR-363 significantly reduced firefly luciferase activity of pMiR-REPORT™ plasmid containing the wild-type MYO1B 3’ UTR or a plasmid
lacking the BS2, implicating miR-363 binds to MYO1B 3’-UTR BS1 to suppress MYO1B expression; *p < 0.001 when compared to WT MYO1B 3’UTR
A B
Fig. 5 SiRNA knockdown of MYO1B reduces cell migration in
HPV-negative SCCHN cells a qRT-PCR of MYO1B expression in JHU-028
48 h post-transfection. b Graph of migratory cells, normalized to negative
Block-it control siRNA; *p< 0.01
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miRNAs, miR-17-92 on chromosome 13, miR-106a-363
on chromosome X, and miR-106b-25 on chromosome 7,
evolved through several deletions and duplications [53].
Since miRNAs from these clusters have similar or identi-
cal seed sequences, they potentially share protein targets.
Thus, it has been hypothesized that miRNAs in the miR-
17 ~ 92 family may possess related functions [32]. Re-
searchers originally named the miR-17-92 polycistron
“OncomiR-1” because the primary transcript represses c-
myc-induced apoptosis in B-cell lymphomas [54]. Mem-
bers of the OncomiR-1 family, miR-106a, −18b, −20b,
−19b, −92-2, and −363 have been implicated in
hematopoietic malignancies and solid tumors of the
breast, colon, lung, pancreas, prostate, and stomach
among others [16, 53, 55–59]. Conversely, the miR-17-
92 cluster has also been found to exhibit tumor suppres-
sive functions. Loss of heterozygosity at the 13q12-q13
region, where the miR-17-92 cluster is located, is linked
with tumor progression and poor prognosis in a number
of solid tumors, including SCC of the larynx, retinoblast-
oma, hepatocellular carcinoma, and nasopharyngeal car-
cinoma [60–65]. One study observed deletion of the
miR-17-92 cluster in 16.5 % of ovarian cancers, 21.9 %
of breast cancers, and 20.0 % of melanomas [66].
The precise role of miR-363 in tumorigenesis re-
mains a controversial topic. MiR-363 has been noted
to carry tumor suppressive properties in neuroblast-
oma, hepatocellular carcinoma, and colorectal cancer
[34–36]. Recently, miR-363 has been reported to
negatively regulate myeloid cell leukemia-1 (Mcl-2),
an anti-apoptotic protein from the Bcl-2 family, and
sensitize breast cancer cells to cisplatin [67]. Con-
versely, it has been shown to target pro-apoptotic
caspases in glioblastoma, thereby acting as an onco-
miR [68]. We speculate that the role of miRNAs as
oncogenes or tumor suppressors may be tissue-
specific. The targets of a particular miRNA may vary
in different cell types and tissues based on the ex-
pression levels of the miRNA and its potential mRNA
targets, differential expression of mRNA binding pro-
teins, and alternative processing of mRNAs [69, 70].
Thus, it is not always feasible to extrapolate a miR-
NA’s functional role based on its cluster or its impli-
cation in a different tissue type.
After reporting miR-363 upregulation in HPV-positive
cell lines in our previous study [30], we sought to corrobor-
ate our findings in SCCHN tumors In the present study,
we confirmed miR-363 overexpression in HPV-positive tu-
mors in TCGA and the UPCI patient cohorts. Our func-
tional phenotypic studies revealed that miR-363 inhibits
SCCHN cell migration and invasion, in part, due to inhib-
ition of MYO1B expression. We also performed the well-
established luciferase reporter assay, to confirm MYO1B as
miR-363 target. A correlative decrease in mRNA and
protein levels of MYO1B was observed following miR-363
expression. Similarly, Sun et al. correlated decreased miR-
363 levels in SCCHN tumor tissues with increased rates of
sentinel lymph node metastasis, though HPV status was
not examined [33]. This group identified another miR-363
target, podoplanin (PDPN), a protein involved in cell motil-
ity [33]. Taken together, these results suggest that the over-
expression of miR-363, and subsequent decrease in
MYO1B and PDPN, is one pathway by which metastasis
may be reduced in HPV-positive SCCHN.
Despite having a milder clinical course, HPV-positive,
p16-positive SCCHN tends to have increased nodal
metastasis, but comparable rates of distant metastasis
versus HPV-negative SCCHN [71, 72]. The mechanism
underlying this phenomenon is yet to be elucidated.
Some studies note that HPV-positivity is a factor associ-
ated with poorly differentiated tumors, which may, result
in early lymphatic spread [73–75]. The heterogeneity of
head and neck tumors in combination with HPV infec-
tion may cause complex molecular perturbations in the
cell and differences in survival and migration pathways
that are affected may affect chemotherapy or radiation
resistance and therefore prognosis of HPV-positive vs.
HPV-negative SCCHN. Finally, we also delineate a link
between miR-363 and MYO1B in the setting of HPV-
positive SCCHN.
Conclusion
In summary, we have shown that miR-363 is upregulated
in HPV-positive SCCHN tumors. Through in vitro
models, we have demonstrated that miR-363 decreases
migration of SCCHN cells by targeting myosin 1B, a mo-
tility protein. The clinical relevance of increased miR-
363 and diminished MYO1B expression in HPV-positive
SCCHN will be the subject of future investigation.
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